Compare Davita Inc (DVA) vs Chart Industries Inc (GTLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Chart Industries Inc — how do they compare? Davita Inc trades at $230.51 (market cap $14.92B), while Chart Industries Inc trades at $209.88 (market cap $10.05B). The key difference: Davita Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| DVA | GTLS | |
|---|---|---|
Market Cap | $14.92B | $10.05B |
Sector | Health | Technology |
52-Week High | $235.71 | $209.91 |
52-Week Low | $103.87 | $164.90 |
Enterprise Value | $27.47B | $13.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
GTLS trades at $209.79, showing minimal daily movement with a -0.04% decline. The stock maintains a bullish technical signal despite recent earnings misses, with Q2 2026 results pending. Valuation metrics show elevated P/E at 629.67 but reasonable P/S at 2.33. The company faces profitability challenges with negative net income margin and ROE, though operating cash flow remains positive at $293M. Recent news highlights Baker Hughes' $13.6 billion acquisition progressing through regulatory approval.
The outlook remains cautiously optimistic given strong analyst support (54% buy rating) and the pending acquisition catalyst. However, consecutive earnings misses and negative profitability metrics present near-term risks. The technical setup suggests potential support at current levels, but fundamental improvement is needed to justify the premium valuation multiple.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Chart Industries Inc
Chart Industries is a leading manufacturer of highly engineered cryogenic equipment. Its products are used throughout the liquid gas supply chain, including clean energy applications like hydrogen and LNG.
Read more on GTLS →
